Search Results - "Khalil, Mazen Y."

A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab by Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.

“…Summary This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered…”
Get full text

Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer by Khalil, Mazen Y, Grandis, Jennifer R, Shin, Dong M

“…Overexpression of epidermal growth factor receptor (EGFR) in epithelial tumors, including head and neck, lung, breast, colon and other solid tumors, has…”
Get full text

Advances in the management of malignant mesothelioma by Khalil, Mazen Y, Mapa, Marissa, Shin, Hyung Ju C, Shin, Dong M

“…Malignant mesotheliomas are very aggressive tumors that originate from mesothelial cells, which form the serosal lining of the pleura, pericardial, and…”
Get full text

Effect of Environment and Research Participant Characteristics on Data Quality by Drew, Barbara L., Mion, Lorraine C., Meldon, Stephen W., Khalil, Mazen Y., Beaver, Andrew, Ghazal-Haddad, Lisa

“…The purpose of this study, a component of a randomized clinical trial, was to assess the influence of the emergency department environment and participant…”
Get full text

A phase 1/2 trial of ublituximab, a novel anti‐ CD 20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab by Sawas, Ahmed, Farber, Charles M., Schreeder, Marshall T., Khalil, Mazen Y., Mahadevan, Daruka, Deng, Changchun, Amengual, Jennifer E., Nikolinakos, Petros G., Kolesar, Jill M., Kuhn, John G., Sportelli, Peter, Miskin, Hari P., O'Connor, Owen A.

“…This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐…”
Get full text

A phase I trial of ublituximab (TG-1101), a novel glycoengineered anti-CD20 monoclonal antibody (mAb) in B-cell non-Hodgkin lymphoma patients with prior exposure to rituximab by O'Connor, Owen A., Deng, Changchun, Amengual, Jennifer Effie, Khalil, Mazen Y., Schreeder, Marshall T., Mahadevan, Daruka, Nikolinakos, Petros, Sawas, Ahmed, Zain, Jasmine M., Patterson, Molly, Moon, Amber, Pauli, Emily K., Cutter, Kathy, Mackenzie, Michelle Ann, Brotherton, Marnie, Hodgson, Jamie, Cooper, Christen N, Sportelli, Peter, Miskin, Hari P., Farber, Charles Michael

“…Abstract only…”
Get full text